secwatch.observer — SEC 8-K summary
======================================

Issuer:     Tempest Therapeutics, Inc. (TPST)
CIK:        0001544227
Form:       8-K
Filed at:   2026-08-13T20:36:03+00:00
Accession:  0001193125-26-349374
Event type: earnings
Sentiment:  positive
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Tempest Q2 net loss $5.2M; TPST-4003 collaboration with Senlang, first dosing Q4 2026
--------------------------------------------------------------------------------

- Q2 net loss $5.2M ($0.34/share) vs $7.9M ($2.07) year ago; cash $0.8M at June 30.
- Collaboration with Senlang Biotechnology for TPST-4003 in vivo CAR-T; first dosing expected Q4 2026, data H1 2027.
- TPST-2003 trials: 100% complete response in 15 CAR-T-naive evaluable patients; no Grade ≥3 CRS/ICANS.
- Appointed Drake Richey and John Yee to board; Andrew Fang as Head of Business Development.
- Warrant inducement raised ~$2M gross proceeds; H1 cash used in ops $10.4M.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1544227/000119312526349374/0001193125-26-349374-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1544227/000119312526349374/tpst-20260813.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-349374

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer